Technical setup is a breakdown setup, not a coiled spring: PEP has been below its 200 SMA for 7 consecutive months, RSI shows bearish non-confirmation (price made higher high to 144.67 while RSI peaked at 61.95, lower than July peaks), and MACD histogram flipped negative at −0.12 two weeks after a bullish crossover.

• PEP below 200 SMA since early February 2026
• 50 SMA rolled from $150.90 (June 4) to $139.75 (September 2), −7.4% slope in 90 days
• 200 SMA declining from ~$147.62 to ~$147.17
• RSI peaked at 61.95 on August 24 vs. earlier July peaks
• MACD histogram flipped negative at −0.12
• 10.19 million shares traded on August 25 vs. typical 6–8M
• Distribution at $142 area right near August swing high

↩ rebuts: “Bull's 'coiled spring' technical thesis”

Q2 2026 'reacceleration' is one-time optical benefit from Q1 2025 impairment base, not operational improvement. FY2025 EPS fell −13.7% YoY and FY2025 revenue grew only ~2.3%. The TTM operating margin of 16.84% includes a quarter where impairment was reversed; normalized margin is 14–15%, actually below the 14.06% FY2024 print.

• FY 2024: Revenue $91.85B, Net Income $9.58B, EPS $6.95
• FY 2025: Revenue $93.93B, Net Income $8.24B, EPS $6.00
• FY 2025 EPS dropped to $6.00 from $6.95 in 2024, −13.7% annual decline
• FY 2025 revenue grew only ~2.3% over FY 2024
• Q2 2026: Revenue $24.18B, Net Income $2.98B, EPS $2.18
• Q1 2025 EPS depressed by $1.86B impairment charge
• TTM operating margin 16.84% includes impairment reversal; normalized is 14–15%
• 14.06% FY2024 operating margin

↩ rebuts: “Bull's 'reacceleration' and 'margin expansion' thesis”

Dividend coverage is razor-thin at 1.004x FCF ($7.67B FCF vs $7.64B dividends paid), with only $30M buffer. Rising interest expense (+37% from $819M to $1.12B) directly compresses FCF in a higher-for-longer rate environment. Net debt at $42.96B with D/E 239% is worse coverage than Chevron's.

• 2025 FCF: $7.67B
• 2025 Dividends Paid: $7.64B
• Buffer: $30 million
• Coverage ratio: 1.004x
• Interest Expense: $819M (2023) to $1.12B (2025)
• Rising interest expense: +37%
• Net debt: $42.96B
• D/E 239% vs KO ~150%

↩ rebuts: “Bull's 'stable cash flow profile' claim”

PEP's −18% from 52-week high versus KO's +26% YTD and all-time highs in the same macro environment shows the divergence is about execution, not yield. KO has demonstrated pricing power, volume resilience, and category mix that PEP lacks. Higher PEP yield compensates for higher risk, not a buying opportunity.

• KO: +26% YTD, all-time highs
• PEP: −18% from 52-week high
• PEP yield: 4.23%, KO yield ~2%
• PEP yields 2x KO
• D/E 239% vs KO ~150%
• ROA 8.93% vs KO ~10%+
• Higher yield compensates for higher risk

↩ rebuts: “Bull's 'different buyer, different bid' thesis”

GLP-1 adoption is a 2026–2027 margin headwind, not a 2030 story. 12%+ of US adults have now used GLP-1 drugs with penetration accelerating among middle-income consumers—exactly PEP's core customer base. PEP itself is repositioning the portfolio for a GLP-1 world, acknowledging the risk.

• 12%+ of US adults have now used GLP-1 drugs
• GLP-1 penetration accelerating among middle-income consumers
• PEP repositioning portfolio for GLP-1 world
• Zacks cited 'category pressure'—volume contracting

↩ rebuts: “Bull's 'soft NA demand is in the rearview' and '2030 thesis' argument”

54% September FOMC hike probability and 89% no-cut probability create dividend coverage compression as rising rates raise the floor on yield investors demand. At $140.52 with 4.23% yield, PEP is already below the rate-of-return threshold if 10-year Treasury goes to 4.5%. Rising rates also make PEP's $53.21B debt stack more expensive to service.

• 54% September FOMC hike probability
• 89% no-cut probability
• Current PEP yield: 4.23%
• 10-year Treasury: 4.2% to 4.5%
• PEP price: $140.52
• Total debt: $53.21B

↩ rebuts: “Bull's 'discount-rate damage is in the price' argument”

PEP's TTM P/E of 18.42x is not cheap for 3% revenue growth. P/B of 8.69x is high relative to stockholders' equity of $22.10B against net debt of $42.96B. The equity base is artificially inflated by $42.15B in buybacks. Goodwill and intangibles of $34.27B (31% of total assets) create real impairment risk as demand softens.

• TTM P/E: 18.42x
• Forward P/E: 15.66x
• Forward EPS: $8.98
• PEG: 1.43
• P/B: 8.69x
• Stockholders' equity: $22.10B
• Net debt: $42.96B
• Treasury stock: $42.15B
• Goodwill and intangibles: $34.27B (31% of total assets)
• EV/EBITDA: ~12.4x
• $1.99B impairment in 2025

↩ rebuts: “Bull's 'discounted valuation' thesis”

Six confirmed bearish events outweigh backward-looking dividend history: Ukraine plant damage, four warehouse actions including 105-job cut, confirmed North America soft demand, India relabeling scheme, KO's +26% YTD divergence, and 54% FOMC hike probability. Zero retail engagement means no contrarian bid.

• Ukraine plant damage confirmed
• 4 warehouse actions in 2026 including 105-job cut
• North America soft demand confirmed
• India relabeling scheme—reputational event
• KO at all-time highs +26% YTD
• Consumer staples lagging S&P 500 in 2026
• 54% September FOMC hike probability
• Zero retail engagement on $192B megacap

↩ rebuts: “Bull's dismissal of bearish coverage as 'thesis-driven'”